Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/toxins9090291 http://scihub22266oqcxt.onion/10.3390/toxins9090291 C5618224!5618224 !28925976     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28925976 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28925976 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Toxins+(Basel) 2017 ; 9 (9 ): ä Nephropedia Template TP {{tp|p=28925976 |t=2017. Shiga Toxin Therapeutics: Beyond Neutralization |pdf=|usr=}}{{28925976 }} gab.com Text Shiga Toxin Therapeutics: Beyond Neutralization JO: Toxins (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=28925976 #FOAvip Ribotoxic Shiga toxins are the primary cause of hemolytic uremic syndrome (HUS) in patients infected with Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC), a pathogen class responsible for epidemic outbreaks of gastrointestinal disease around the globe. HUS is a leading cause of pediatric renal failure in otherwise healthy children, resulting in a mortality rate of 10% and a chronic morbidity rate near 25%. There are currently no available therapeutics to prevent or treat HUS in STEC patients despite decades of work elucidating the mechanisms of Shiga toxicity in sensitive cells. The preclinical development of toxin-targeted HUS therapies has been hindered by the sporadic, geographically dispersed nature of STEC outbreaks with HUS cases and the limited financial incentive for the commercial development of therapies for an acute disease with an inconsistent patient population. The following review considers potential therapeutic targeting of the downstream cellular impacts of Shiga toxicity, which include the unfolded protein response (UPR) and the ribotoxic stress response (RSR). Outcomes of the UPR and RSR are relevant to other diseases with large global incidence and prevalence rates, thus reducing barriers to the development of commercial drugs that could improve STEC and HUS patient outcomes. Twit Text FOAVip Shiga Toxin Therapeutics: Beyond Neutralization ????Toxins (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=28925976 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28925976 #FOAvip English Wikipedia <ref>{{Cite pmid|28925976 }}</ref> Shiga Toxin Therapeutics: Beyond Neutralization #MMPMID28925976 Hall G ; Kurosawa S ; Stearns-Kurosawa DJ Toxins (Basel) 2017[Sep]; 9 (9 ): ä PMID28925976 show ga Ribotoxic Shiga toxins are the primary cause of hemolytic uremic syndrome (HUS) in patients infected with Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC), a pathogen class responsible for epidemic outbreaks of gastrointestinal disease around the globe. HUS is a leading cause of pediatric renal failure in otherwise healthy children, resulting in a mortality rate of 10% and a chronic morbidity rate near 25%. There are currently no available therapeutics to prevent or treat HUS in STEC patients despite decades of work elucidating the mechanisms of Shiga toxicity in sensitive cells. The preclinical development of toxin-targeted HUS therapies has been hindered by the sporadic, geographically dispersed nature of STEC outbreaks with HUS cases and the limited financial incentive for the commercial development of therapies for an acute disease with an inconsistent patient population. The following review considers potential therapeutic targeting of the downstream cellular impacts of Shiga toxicity, which include the unfolded protein response (UPR) and the ribotoxic stress response (RSR). Outcomes of the UPR and RSR are relevant to other diseases with large global incidence and prevalence rates, thus reducing barriers to the development of commercial drugs that could improve STEC and HUS patient outcomes. |Animals [MESH] |Escherichia coli Infections/*drug therapy/metabolism [MESH] |Hemolytic-Uremic Syndrome/*drug therapy/metabolism [MESH] |Humans [MESH] |Ribosomes/metabolism [MESH] |Shiga Toxin/chemistry/*toxicity [MESH] |Shiga-Toxigenic Escherichia coli [MESH]Shiga Toxin Therapeutics: Beyond Neutralization (epmc).pdf DeepDyve Pubget Overpricing